Sökning: ((WFRF:(Shiba R.))) >
First on-line surve...
First on-line survey of an international multidisciplinary working group (MightyMedic) on current practice in diagnosis, therapy and follow-up of dyslipidemias
-
Stefanutti, C. (författare)
-
D'Alessandri, G. (författare)
-
Petta, A. (författare)
-
visa fler...
-
Harada-Shiba, M. (författare)
-
Julius, U. (författare)
-
Soran, H. (författare)
-
Moriarty, P. M. (författare)
-
- Romeo, Stefano, 1976 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
-
Drogari, E. (författare)
-
Jaeger, B. R. (författare)
-
MightyMedic Multidisciplinary, Int (författare)
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2015
- 2015
- Engelska.
-
Ingår i: Atherosclerosis Supplements. - : Elsevier BV. - 1567-5688. ; 18, s. 241-250
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- The MightyMedic (Multidisciplinary International Group for Hemapheresis TherapY and MEtabolic DIsturbances Contrast) Working Group has been founded in 2013. The leading idea was to establish an international network of interdisciplinary nature aimed at working to cross national borders research projects, clinical trials, educational initiatives (meetings, workshops, summer schools) in the field of metabolic diseases, namely hyperlipidemias, and diabetes, preventive cardiology, and atherosclerosis. Therapeutic apheresis, its indications and techniques, is a parallel field of investigation. The first on-line survey of the Group has been completed in the first half of 2014. The survey included # 24 Centers in Italy, Germany, Greece, UK, Sweden, Japan and USA. Relevant data have been collected on current practice in diagnosis, therapy and follow-up of dyslipidemias. 240 subjects with hyperlipidemia and treated with lipoprotein apheresis have been reported in the survey, but a large percentage of patients (35%) who could benefit from this therapeutic option are still treated by conventional drug approach. Genetic molecular diagnosis is performed in only 33% of patients while Lipoprotein(a) (Lp(a)) is included in cardiovascular disease risk assessment in 71% of participating Centers. New detailed investigations and prospective multicenter studies are needed to evaluate changes induced by the impact of updated indications and strategies, as well as new treatment options, targeting standardization of therapeutic and diagnostic approaches.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
Nyckelord
- Coronary artery disease
- Dyslipidemia
- Lipoprotein apheresis
- Multicenter study
- Survey
- DENSITY-LIPOPROTEIN-APHERESIS
- ASSOCIATION EXPERT PANEL
- CORONARY-HEART-DISEASE
- FAMILIAL HYPERCHOLESTEROLEMIA
- ITALIAN REGISTRY
- MANAGEMENT
- GUIDELINES
- SOCIETY
- RECOMMENDATIONS
- POPULATION
- Peripheral Vascular Disease
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Stefanutti, C.
-
D'Alessandri, G.
-
Petta, A.
-
Harada-Shiba, M.
-
Julius, U.
-
Soran, H.
-
visa fler...
-
Moriarty, P. M.
-
Romeo, Stefano, ...
-
Drogari, E.
-
Jaeger, B. R.
-
MightyMedic Mult ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
- Artiklar i publikationen
-
Atherosclerosis ...
- Av lärosätet
-
Göteborgs universitet